MARKET

ETON

ETON

Eton Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.57
-0.56
-6.89%
After Hours: 7.60 +0.03 +0.40% 18:18 10/28 EDT
OPEN
8.00
PREV CLOSE
8.13
HIGH
8.03
LOW
7.44
VOLUME
436.94K
TURNOVER
--
52 WEEK HIGH
9.12
52 WEEK LOW
2.500
MARKET CAP
183.01M
P/E (TTM)
-6.5706
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Zacks · 10/21 16:58
FDA accepts Eton application for zonisamide for partial seizures
The FDA has accepted for review Eton Pharmaceuticals's (ETON) marketing application seeking approval for zonisamide oral suspension, for the treatment of partial seizures in patients with epilepsy.Agency date has been set at May
Seekingalpha · 10/15 12:50
Eton Pharmaceuticals Announces Acceptance For Filing Of New Drug Application For Zonisamide Oral Suspension
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension DEER PARK, Ill., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), a specialty
Benzinga · 10/15 12:32
Eton Pharmaceuticals prices offering of 2.8M shares of common stock at $7.00 per share
Eton Pharmaceuticals (ETON) announces the pricing of an underwritten public offering of 2.8M issued shares at a price of $7.00/share.The gross proceeds from the offering are expected to be ~$19.6M.Underwriters'
Seekingalpha · 10/14 12:55
Eton Pharmaceuticals prices equity offering, shares up 5%
Eton Pharmaceuticals (ETON) announces the pricing of an underwritten public offering of 2.8M issued shares at a price of $7.00/share.The gross proceeds from the offering are expected to be ~$19.6M.Underwriters'
Seekingalpha · 10/14 12:55
Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock
DEER PARK, Ill., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the pricing of an underwritten public offering of 2,800,000 shares of its common stock at a price to the public of $7.00 per share, for gross proceeds of $19.6 million. The Company has also granted the underwriters a 45-day option to purchase, at the same price per share as the underwriters paid for the initial shares, an additional 420,000 shares to cover over-allotments in connection with the offering, which if exercised in full would increase the gross proceeds to $22.5 million.The offering is expected to close on or about October 16, 2020, subject to customary closing conditions. Eton Pharmaceuticals intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development activities, capital expenditures, selling, general and administrative costs, and to meet working capital needs. National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), is acting as the sole book-running manager of the offering. The Liquid Venture Partners group at National Securities is responsible for sourcing and executing the offering. The shares described above are being offered by Eton Pharmaceuticals pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement will be filed with the SEC. The final prospectus supplement will be available on the SEC’s website at https://www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A copy of the final prospectus supplement relating to this offering may be obtained, when available, from National Securities Corporation, Attn: Charles Wanyama, ECM -Syndicate, 200 Vesey Street, 25th Floor New York, NY 10281, email: cwanyama@yournational.com, telephone: (212)-417-3634. About Eton Pharmaceuticals Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products in its late-stage pipeline, including five that have been submitted to the FDA.Safe Harbor This press release contains forward-looking statements regarding the expected closing of the public offering and the intended use of proceeds from the offering. The offering is subject to customary closing conditions and there can be no assurance as to whether or when the offering will be completed.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed in the section “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on October 13, 2020. Eton Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.Company Contact: David Krempa dkrempa@etonpharma.com 612-387-3740
GlobeNewswire · 10/14 12:30
Eton Pharmaceuticals initiates equity offering
Eton Pharmaceuticals (ETON) -6% announces public offering to sell common shares.Closing date is October 14, 2020. Net proceeds will be used primarily for general corporate purposes, which may include research and development
Seekingalpha · 10/13 20:08
Eton Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEER PARK, Ill. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Wednesday, October 14, 2020.Eton Pharmaceuticals intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development activities, capital expenditures, selling, general and administrative costs, and to meet working capital needs.National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NASDAQ: NHLD), is acting as the sole book-running manager of the offering. The Liquid Venture Partners group at National Securities is responsible for sourcing and executing the offering.The shares described above are being offered by Eton Pharmaceuticals pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC’s website at https://www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from National Securities Corporation, Attn: Charles Wanyama, ECM -Syndicate, 200 Vesey Street, 25th Floor New York, NY 10281, email: cwanyama@yournational.com, telephone: (212)-417-3634.About Eton Pharmaceuticals Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products in its late-stage pipeline, including five that have been submitted to the FDA.Safe Harbor This press release contains forward-looking statements regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed in the section “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on October 13, 2020. Eton Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.Company Contact: David Krempa dkrempa@etonpharma.com 612-387-3740
GlobeNewswire · 10/13 20:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ETON. Analyze the recent business situations of Eton Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ETON stock price target is 16.00 with a high estimate of 20.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 6.80M
% Owned: 28.14%
Shares Outstanding: 24.18M
TypeInstitutionsShares
Increased
8
840.13K
New
29
561.08K
Decreased
5
565.02K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Independent Director
Norbert Riedel
President/Chief Executive Officer/Director
Sean Brynjelsen
Chief Financial Officer/Treasurer/Secretary
W. Troutman
Senior Vice President
Ingrid Hoos
Director
Mark Baum
Independent Director
Charles Casamento
Independent Director
Paul Maier
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ETON
Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eton Pharmaceuticals Inc stock information, including NASDAQ:ETON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ETON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ETON stock methods without spending real money on the virtual paper trading platform.